NCT03274661: Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors

NCT03274661
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: DNA damage repair mutations
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Therapeutic Antibody, Immunotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 99 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are only eligible for the dose escalation phase (not the expansion phase); Trial is specifically investigating the Fanconi Anemia (FANCA) pathway – a DNA repair mutation, though it is not required to participate.
Exclusions: Patients with leptomeningeal disease or untreated symptomatic brain metastases that require treatment – see trial for details
https://ClinicalTrials.gov/show/NCT03274661

Comments are closed.

Up ↑